Skip to main content
. Author manuscript; available in PMC: 2013 Sep 15.
Published in final edited form as: Clin Cancer Res. 2012 Jul 23;18(18):4986–4996. doi: 10.1158/1078-0432.CCR-12-0792

Figure 2.

Figure 2

(A) pSTAT3 protein expression is increased in cetuximab resistant cancer cells. Cetuximab sensitive parental T24 cells and isogenic clones demonstrating acquired resistance to cetuximab (T24 PR1, T24 PR2 and T24 PR3) were subjected to immunoblotting for pSTAT3Tyr705 and STAT3. β-tubulin was used as a loading control. (B) pSTAT3 expression was increased by 3.2–3.9-fold in the cetuximab resistant T24 PR1, T24 PR2 and T24 PR3 cells compared to the isogenic cetuximab sensitive T24 cells (p=0.03). The experiment was repeated four times with similar results. (C) IL6-secreted protein levels increase in cetuximab resistant bladder cancer cells (T24 PR1, T24 PR2 and T24 PR3, p~0.005) compared to the sensitive counterpart (T24) as confirmed by ELISA.